I think that the elanco fda approval may be another 3 to 4 months.I would be very surprised if elli lilly is not talking to acr re their luramist product as they have already completed alot of due diligence on the delivery system for the axiron product.When the axiron product is approved by the fda early next year i believe the stock will increase by $1.00 + tax free (very handy return one would have to say 50% tax free)
rbs valutaion $3.19, page-3
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
